TITLE:
Real-World Utilization Pattern, Safety and Effectiveness of Rosuvastatin (RoshalTM) in Patients with Dyslipidemia in Ghana: Results from the PEARL Prospective Observational Study
AUTHORS:
Christian Kubuafor
KEYWORDS:
Dyslipidemia, Rosuvastatin, LDL Cholesterol, Ghana, Statin Therapy, Cardiovascular Risk
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.16 No.9,
September
9,
2026
ABSTRACT: Background: Dyslipidemia is a major modifiable cardiovascular risk factor and contributes significantly to the burden of cardiovascular disease globally and in sub-Saharan Africa. Data regarding real-world effectiveness and safety of statin therapy among Ghanaian patients remain limited. Methods: This prospective observational study enrolled 419 adult patients with dyslipidemia receiving rosuvastatin (RoshalTM) therapy in Ghana. Patients were followed for 24 weeks. Lipid parameters, treatment adherence, dosage patterns, adverse events, and physician global assessment of treatment efficacy and safety were evaluated. Changes in lipid parameters from baseline to follow-up visits were analyzed using paired t-tests. Results: The mean age of participants was 53.97 ± 13.41 years, and females constituted 59.6% of the cohort. Poor dietary habits (61.3%) and physical inactivity (42.2%) were the most common cardiovascular risk factors. Hypertension was the commonest comorbidity (61.1%), followed by diabetes mellitus (22.9%). Rosuvastatin (RoshalTM) therapy resulted in significant reductions in lipid parameters over time. Mean LDL-C decreased from 4.14 ± 0.86 mmol/L at baseline to 3.07 ± 0.77 mmol/L at visit 2, representing a 25.85% reduction (p Conclusion: Rosuvastatin therapy (RoshalTM) was effective and well tolerated among Ghanaian patients with dyslipidemia, producing significant improvements in lipid parameters and cardiovascular risk indicators. These findings support the role of rosuvastatin as an effective therapeutic option for dyslipidemia management in routine clinical practice in Ghana.